KRAS and colonic neoplasm: However, this crosstalk may also restrict p38γ activity to phosphorylate and/or to enhance PTPH1 dephosphorylating oncogenic substrates such as EGFR to confer the phenotype of KRAS-mutant colon cancer resistant to EGFR inhibitors [54].